O	0	7	Isotype	Isotype	NN	B-NP
O	7	8	-	-	HYPH	I-NP
O	8	16	specific	specific	JJ	I-NP
O	17	27	inhibitors	inhibitor	NNS	I-NP
O	28	30	of	of	IN	B-PP
O	31	34	the	the	DT	B-NP
O	35	45	glycolytic	glycolytic	JJ	I-NP
O	46	49	key	key	JJ	I-NP
O	50	59	regulator	regulator	NN	I-NP
O	60	68	pyruvate	pyruvate	NN	I-NP
O	69	75	kinase	kinase	NN	I-NP
O	76	83	subtype	subtype	NN	I-NP
O	84	86	M2	M2	NN	I-NP
O	87	97	moderately	moderately	RB	B-ADVP
O	98	108	decelerate	decelerate	VBP	B-VP
B-Cell	109	114	tumor	tumor	NN	B-NP
I-Cell	115	119	cell	cell	NN	I-NP
O	120	133	proliferation	proliferation	NN	I-NP
O	133	134	.	.	.	O

B-Cell	136	141	Tumor	Tumor	NN	B-NP
I-Cell	142	147	cells	cell	NNS	I-NP
O	148	155	express	express	VBP	B-VP
O	156	159	the	the	DT	B-NP
O	160	170	glycolytic	glycolytic	JJ	I-NP
O	171	180	regulator	regulator	NN	I-NP
O	181	189	pyruvate	pyruvate	NN	I-NP
O	190	196	kinase	kinase	NN	I-NP
O	197	204	subtype	subtype	NN	I-NP
O	205	207	M2	M2	NN	I-NP
O	208	209	(	(	(	O
O	209	211	M2	M2	NN	B-NP
O	211	212	-	-	HYPH	B-NP
O	212	214	PK	PK	NN	I-NP
O	214	215	)	)	)	O
O	215	216	,	,	,	O
O	217	222	which	which	WDT	B-NP
O	223	226	can	can	MD	B-VP
O	227	232	occur	occur	VB	I-VP
O	233	235	in	in	IN	B-PP
O	236	237	a	a	DT	B-NP
O	238	248	tetrameric	tetrameric	JJ	I-NP
O	249	253	form	form	NN	I-NP
O	254	258	with	with	IN	B-PP
O	259	263	high	high	JJ	B-NP
O	264	272	affinity	affinity	NN	I-NP
O	273	275	to	to	TO	B-PP
O	276	279	its	its	PRP$	B-NP
O	280	289	substrate	substrate	NN	I-NP
O	290	309	phosphoenolpyruvate	phosphoenolpyruvate	NN	I-NP
O	310	311	(	(	(	O
O	311	314	PEP	PEP	NN	B-NP
O	314	315	)	)	)	O
O	316	319	and	and	CC	O
O	320	321	a	a	DT	B-NP
O	322	329	dimeric	dimeric	JJ	I-NP
O	330	334	form	form	NN	I-NP
O	335	339	with	with	IN	B-PP
O	340	341	a	a	DT	B-NP
O	342	345	low	low	JJ	I-NP
O	346	349	PEP	PEP	NN	I-NP
O	350	358	affinity	affinity	NN	I-NP
O	358	359	.	.	.	O

O	360	363	The	The	DT	B-NP
O	364	374	transition	transition	NN	I-NP
O	375	382	between	between	IN	B-PP
O	383	387	both	both	DT	B-NP
O	388	401	conformations	conformation	NNS	I-NP
O	402	413	contributes	contribute	VBZ	B-VP
O	414	416	to	to	TO	B-PP
O	417	420	the	the	DT	B-NP
O	421	428	control	control	NN	I-NP
O	429	431	of	of	IN	B-PP
O	432	442	glycolysis	glycolysis	NN	B-NP
O	443	446	and	and	CC	O
O	447	449	is	be	VBZ	B-VP
O	450	459	important	important	JJ	B-ADJP
O	460	463	for	for	IN	B-PP
B-Cell	464	469	tumor	tumor	NN	B-NP
I-Cell	470	474	cell	cell	NN	I-NP
O	475	488	proliferation	proliferation	NN	I-NP
O	489	492	and	and	CC	I-NP
O	493	501	survival	survival	NN	I-NP
O	501	502	.	.	.	O

O	503	507	Here	Here	RB	B-ADVP
O	508	510	we	we	PRP	B-NP
O	511	519	targeted	target	VBD	B-VP
O	520	522	M2	M2	NN	B-NP
O	522	523	-	-	HYPH	B-NP
O	523	525	PK	PK	NN	I-NP
O	526	528	by	by	IN	B-PP
O	529	538	synthetic	synthetic	JJ	B-NP
O	539	546	peptide	peptide	NN	I-NP
O	547	555	aptamers	aptamer	NNS	I-NP
O	555	556	,	,	,	O
O	557	562	which	which	WDT	B-NP
O	563	575	specifically	specifically	RB	B-ADVP
O	576	580	bind	bind	VBP	B-VP
O	581	583	to	to	TO	B-PP
O	584	586	M2	M2	NN	B-NP
O	586	587	-	-	HYPH	I-NP
O	587	589	PK	PK	NN	I-NP
O	590	593	and	and	CC	O
O	594	599	shift	shift	VB	B-VP
O	600	603	the	the	DT	B-NP
O	604	613	isoenzyme	isoenzyme	NN	I-NP
O	614	618	into	into	IN	B-PP
O	619	622	its	its	PRP$	B-NP
O	623	626	low	low	JJ	I-NP
O	627	635	affinity	affinity	NN	I-NP
O	636	643	dimeric	dimeric	JJ	I-NP
O	644	656	conformation	conformation	NN	I-NP
O	656	657	.	.	.	O

O	658	661	The	The	DT	B-NP
O	662	669	aptamer	aptamer	NN	I-NP
O	669	670	-	-	HYPH	B-NP
O	670	677	induced	induce	VBN	I-NP
O	678	690	dimerization	dimerization	NN	I-NP
O	691	694	and	and	CC	I-NP
O	695	707	inactivation	inactivation	NN	I-NP
O	708	710	of	of	IN	B-PP
O	711	713	M2	M2	NN	B-NP
O	713	714	-	-	HYPH	B-NP
O	714	716	PK	PK	NN	I-NP
O	717	720	led	lead	VBD	B-VP
O	721	723	to	to	TO	B-PP
O	724	725	a	a	DT	B-NP
O	726	737	significant	significant	JJ	I-NP
O	738	746	decrease	decrease	NN	I-NP
O	747	749	in	in	IN	B-PP
O	750	753	the	the	DT	B-NP
O	754	756	PK	PK	NN	I-NP
O	757	761	mass	mass	NN	I-NP
O	761	762	-	-	HYPH	B-NP
O	762	768	action	action	NN	I-NP
O	769	774	ratio	ratio	NN	I-NP
O	775	777	as	as	RB	B-CONJP
O	778	782	well	well	RB	I-CONJP
O	783	785	as	as	IN	I-CONJP
O	786	789	ATP	ATP	NN	B-NP
O	789	790	:	:	:	O
O	790	793	ADP	ADP	NN	B-NP
O	794	799	ratio	ratio	NN	I-NP
O	800	802	in	in	IN	B-PP
O	803	806	the	the	DT	B-NP
O	807	813	target	target	NN	I-NP
B-Cell	814	819	cells	cell	NNS	I-NP
O	819	820	.	.	.	O

O	821	832	Furthermore	Furthermore	RB	B-ADVP
O	832	833	,	,	,	O
O	834	837	the	the	DT	B-NP
O	838	848	expression	expression	NN	I-NP
O	849	851	of	of	IN	B-PP
O	852	854	M2	M2	NN	B-NP
O	854	855	-	-	HYPH	B-NP
O	855	857	PK	PK	NN	I-NP
O	857	858	-	-	HYPH	O
O	858	865	binding	bind	VBG	B-VP
O	866	873	peptide	peptide	NN	B-NP
O	874	882	aptamers	aptamer	NNS	I-NP
O	883	893	moderately	moderately	RB	B-ADVP
O	894	901	reduced	reduce	VBD	B-VP
O	902	905	the	the	DT	B-NP
O	906	912	growth	growth	NN	I-NP
O	913	915	of	of	IN	B-PP
O	916	928	immortalized	immortalize	VBN	B-NP
B-Cell	929	935	NIH3T3	NIH3T3	NN	I-NP
I-Cell	936	940	cell	cell	NN	I-NP
I-Cell	941	952	populations	population	NNS	I-NP
O	953	955	by	by	IN	B-PP
O	956	968	decelerating	decelerate	VBG	B-VP
B-Cell	969	973	cell	cell	NN	B-NP
O	974	987	proliferation	proliferation	NN	I-NP
O	987	988	,	,	,	O
O	989	992	but	but	CC	O
O	993	1000	without	without	IN	B-PP
O	1001	1010	affecting	affect	VBG	B-VP
O	1011	1020	apoptotic	apoptotic	JJ	B-NP
B-Cell	1021	1025	cell	cell	NN	I-NP
O	1026	1031	death	death	NN	I-NP
O	1031	1032	.	.	.	O

O	1033	1041	Moreover	Moreover	RB	B-ADVP
O	1041	1042	,	,	,	O
O	1043	1046	the	the	DT	B-NP
O	1047	1049	M2	M2	NN	I-NP
O	1049	1050	-	-	HYPH	B-NP
O	1050	1052	PK	PK	NN	I-NP
O	1052	1053	-	-	HYPH	O
O	1053	1060	binding	bind	VBG	B-VP
O	1061	1068	peptide	peptide	NN	B-NP
O	1069	1077	aptamers	aptamer	NNS	I-NP
O	1078	1082	also	also	RB	B-ADVP
O	1083	1090	reduced	reduce	VBD	B-VP
O	1091	1094	the	the	DT	B-NP
O	1095	1108	proliferation	proliferation	NN	I-NP
O	1109	1113	rate	rate	NN	I-NP
O	1114	1116	of	of	IN	B-PP
O	1117	1122	human	human	JJ	B-NP
B-Cell	1123	1124	U	U	NN	I-NP
I-Cell	1124	1125	-	-	HYPH	I-NP
I-Cell	1125	1126	2	2	CD	I-NP
I-Cell	1127	1129	OS	OS	NN	I-NP
I-Cell	1130	1142	osteosarcoma	osteosarcoma	NN	I-NP
I-Cell	1143	1148	cells	cell	NNS	I-NP
O	1148	1149	.	.	.	O

O	1150	1152	In	In	IN	B-PP
O	1153	1156	the	the	DT	B-NP
O	1157	1164	present	present	JJ	I-NP
O	1165	1170	study	study	NN	I-NP
O	1170	1171	,	,	,	O
O	1172	1174	we	we	PRP	B-NP
O	1175	1184	developed	develop	VBD	B-VP
O	1185	1188	the	the	DT	B-NP
O	1189	1194	first	first	JJ	I-NP
O	1195	1203	specific	specific	JJ	I-NP
O	1204	1214	inhibitors	inhibitor	NNS	I-NP
O	1215	1217	of	of	IN	B-PP
O	1218	1221	the	the	DT	B-NP
O	1222	1230	pyruvate	pyruvate	NN	I-NP
O	1231	1237	kinase	kinase	NN	I-NP
O	1238	1247	isoenzyme	isoenzyme	NN	I-NP
O	1248	1252	type	type	NN	I-NP
O	1253	1255	M2	M2	NN	I-NP
O	1256	1259	and	and	CC	O
O	1260	1267	present	present	JJ	B-NP
O	1268	1276	evidence	evidence	NN	I-NP
O	1277	1281	that	that	IN	B-SBAR
O	1282	1287	these	these	DT	B-NP
O	1288	1298	inhibitors	inhibitor	NNS	I-NP
O	1299	1309	moderately	moderately	RB	B-ADVP
O	1310	1320	decelerate	decelerate	VBP	B-VP
B-Cell	1321	1326	tumor	tumor	NN	B-NP
I-Cell	1327	1331	cell	cell	NN	I-NP
O	1332	1345	proliferation	proliferation	NN	I-NP
O	1345	1346	.	.	.	O

